Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group.

N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.

2.

Five-year clinical follow-up after sirolimus-eluting stent implantation for the treatment of coronary in-stent restenosis.

Schiele TM, Leibig M, Rieber J, König A, Krötz F, Sohn HY, Klauss V.

Coron Artery Dis. 2011 May;22(3):188-93. doi: 10.1097/MCA.0b013e3283423714.

PMID:
21394029
3.

mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.

Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, Veasey SC, Ihida-Stansbury K, Jones PL, Goncharova EA.

FASEB J. 2011 Jun;25(6):1922-33. doi: 10.1096/fj.10-175018. Epub 2011 Mar 2.

4.

Epithelial EGF receptor signaling mediates airway hyperreactivity and remodeling in a mouse model of chronic asthma.

Le Cras TD, Acciani TH, Mushaben EM, Kramer EL, Pastura PA, Hardie WD, Korfhagen TR, Sivaprasad U, Ericksen M, Gibson AM, Holtzman MJ, Whitsett JA, Hershey GK.

Am J Physiol Lung Cell Mol Physiol. 2011 Mar;300(3):L414-21. doi: 10.1152/ajplung.00346.2010. Epub 2010 Dec 17.

5.

Activating mutations of TOR (target of rapamycin).

Hardt M, Chantaravisoot N, Tamanoi F.

Genes Cells. 2011 Feb;16(2):141-51. doi: 10.1111/j.1365-2443.2010.01482.x. Epub 2011 Jan 7. Review.

6.

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.

Powell JD, Delgoffe GM.

Immunity. 2010 Sep 24;33(3):301-11. doi: 10.1016/j.immuni.2010.09.002. Review.

7.

Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus.

Giordano A.

Curr Opin Drug Discov Devel. 2010 Mar;13(2):159-68. Review.

PMID:
20205050
8.

mTOR signaling at a glance.

Laplante M, Sabatini DM.

J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94. doi: 10.1242/jcs.051011. Review. No abstract available.

9.

Noninflammatory mechanisms of airway hyper-responsiveness in bronchial asthma: an overview.

Baroffio M, Barisione G, Crimi E, Brusasco V.

Ther Adv Respir Dis. 2009 Aug;3(4):163-74. doi: 10.1177/1753465809343595. Epub 2009 Aug 6. Review.

PMID:
19661157
10.

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA.

Nature. 2009 Jul 16;460(7253):392-5. doi: 10.1038/nature08221. Epub 2009 Jul 8.

11.

Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.

Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, Hardie WD.

Am J Respir Cell Mol Biol. 2009 Nov;41(5):562-72. doi: 10.1165/rcmb.2008-0377OC. Epub 2009 Feb 24.

12.

Early growth response-1 suppresses epidermal growth factor receptor-mediated airway hyperresponsiveness and lung remodeling in mice.

Kramer EL, Mushaben EM, Pastura PA, Acciani TH, Deutsch GH, Khurana Hershey GK, Korfhagen TR, Hardie WD, Whitsett JA, Le Cras TD.

Am J Respir Cell Mol Biol. 2009 Oct;41(4):415-25. doi: 10.1165/rcmb.2008-0470OC. Epub 2009 Feb 2.

13.

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Krymskaya VP, Goncharova EA.

Cell Cycle. 2009 Feb 1;8(3):403-13. Epub 2009 Feb 6. Review.

14.

Conditional expression of genes in the respiratory epithelium in transgenic mice: cautionary notes and toward building a better mouse trap.

Perl AK, Zhang L, Whitsett JA.

Am J Respir Cell Mol Biol. 2009 Jan;40(1):1-3. doi: 10.1165/rcmb.2008-0011ED. No abstract available.

15.

Diagnosis and treatment of refractory asthma.

Urso DL, Vincenzo D, Pignataro E, Acri P, Cucinotta G.

Eur Rev Med Pharmacol Sci. 2008 Sep-Oct;12(5):315-20. Review.

PMID:
19024216
16.

Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases.

Burgel PR, Nadel JA.

Eur Respir J. 2008 Oct;32(4):1068-81. doi: 10.1183/09031936.00172007. Review.

17.

EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.

Hardie WD, Davidson C, Ikegami M, Leikauf GD, Le Cras TD, Prestridge A, Whitsett JA, Korfhagen TR.

Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1217-25. doi: 10.1152/ajplung.00020.2008. Epub 2008 Apr 18.

18.

The synergistic interactions of allergic lung inflammation and intratracheal cationic protein.

Bates JH, Cojocaru A, Haverkamp HC, Rinaldi LM, Irvin CG.

Am J Respir Crit Care Med. 2008 Feb 1;177(3):261-8. Epub 2007 Oct 25.

19.

Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma.

Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, Chung KF, Laviolette M; RISA Trial Study Group.

Am J Respir Crit Care Med. 2007 Dec 15;176(12):1185-91. Epub 2007 Sep 27.

PMID:
17901415
20.

Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms.

Gupte GL, Mahadevan S, Clarke JR, Alton H, Beath SV.

World J Gastroenterol. 2007 Oct 14;13(38):5151-3.

Items per page

Supplemental Content

Write to the Help Desk